Australia's most trusted
source of pharma news
Posted 7 February 2024 PM
Johnson & Johnson is staring down a looming patent cliff for its blockbuster monoclonal antibody, Stelara, reassuring investors it has the pipeline to counter a hit to revenue as biosimilars enter the market this year.
The company has a firm plan to combat the impact of the exclusivity loss, centred around a buoyant pipeline, revealing it expects one-third of its revenue to be generated by new products by 2027.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.